By Counterforce Health Team in Pemazyre (pemigatinib) —

If Pemazyre (Pemigatinib) Isn't Approved by Aetna CVS Health in Ohio: Formulary Alternatives & Exception Paths

Answer Box: Fast Track to Pemazyre Coverage

If Aetna CVS Health denies Pemazyre (pemigatinib) in Ohio, you have three main paths: formulary exception request (if non-formulary), prior authorization appeal (if denied for medical necessity), or trying alternative FGFR inhibitors first. Most denials stem from missing FGFR2 fusion test results or inadequate prior therapy documentation. Start by gathering your molecular pathology report and treatment history, then submit a formulary exception through your prescriber within 180 days. Ohio residents get external review rights through the Department of Insurance if internal appeals fail.

Table of Contents

When Alternatives Make Sense

Formulary alternatives to Pemazyre make clinical sense in specific situations, but the landscape for FGFR inhibitors in cholangiocarcinoma and myeloid/lymphoid neoplasms is limited. Here's when to consider them:

Clinical Scenarios for Alternatives:

  • Aetna CVS Health requires step therapy through another FGFR inhibitor first
  • Pemazyre is completely non-formulary on your specific plan
  • Your FGFR alteration responds better to a different inhibitor
  • Cost considerations make an alternative more accessible

When Alternatives Don't Work:

  • FGFR1 rearrangements in myeloid/lymphoid neoplasms (Pemazyre is often the only targeted option)
  • Prior failure of infigratinib with documented progression
  • Specific FGFR2 fusion subtypes that respond poorly to other inhibitors
Note: Most Aetna CVS Health plans don't list specific preferred FGFR inhibitors in their public formularies, making prior authorization necessary for all options in this class.

Typical Alternatives by Drug Class

FGFR Inhibitors (Targeted Therapy)

Infigratinib (Truseltiq)

  • FDA-approved for FGFR2 fusion/rearrangement-positive cholangiocarcinoma
  • Often considered first-line FGFR inhibitor by some payers
  • Requires similar molecular testing and monitoring as Pemazyre
  • Coverage status with Aetna CVS Health: Prior authorization required

Futibatinib (Lytgobi)

  • Newer FGFR inhibitor with potentially higher response rates
  • Effective after infigratinib failure in some patients
  • May be easier to get approved if positioned as second-line FGFR therapy
  • Coverage status: Generally covered with prior authorization for FGFR2+ cholangiocarcinoma

Erdafitinib (Balversa)

  • Primarily approved for bladder cancer, not cholangiocarcinoma
  • Off-label use rare and typically not covered by Aetna CVS Health
  • Consider only in clinical trial settings

Conventional Chemotherapy Options

First-line combinations:

  • Gemcitabine + cisplatin (standard of care)
  • Gemcitabine + cisplatin + durvalumab (TOPAZ-1 regimen)
  • Generally well-covered by Aetna CVS Health with minimal prior authorization

Second-line options:

  • FOLFOX (5-fluorouracil, leucovorin, oxaliplatin)
  • Capecitabine-based regimens
  • Immunotherapy combinations where appropriate

Pros and Cons Overview

Coverage Considerations

Alternative Coverage Likelihood Testing Requirements Monitoring Needs
Infigratinib High with PA FGFR2 fusion required Ophthalmologic, phosphate
Futibatinib High with PA FGFR2 fusion required Similar to Pemazyre
Gemcitabine/cisplatin Excellent Standard staging Routine chemo monitoring
FOLFOX Excellent None specific Standard protocols

Access Considerations

Advantages of trying alternatives first:

  • May satisfy step therapy requirements for eventual Pemazyre approval
  • Some have longer track records with payers
  • Could provide clinical benefit while appealing for Pemazyre

Disadvantages:

  • Delays access to potentially optimal therapy
  • May not be effective for your specific FGFR alteration
  • Time lost during disease progression
From our advocates: We've seen patients successfully use a "trial and document" approach—starting with the payer's preferred FGFR inhibitor while simultaneously appealing for their physician's first choice. This strategy can satisfy step therapy requirements while building a stronger case for the preferred agent if the alternative doesn't work.

Exception Strategy for Pemazyre

When to Request an Exception

File a formulary exception request with Aetna CVS Health if:

  • Pemazyre is non-formulary or has restrictive coverage
  • Step therapy requirements seem inappropriate for your case
  • Quantity limits don't match your prescribed dosing
  • You've already failed alternatives

Evidence That Helps Your Exception

Required Clinical Documentation:

  1. FGFR2/FGFR1 molecular test results - This is non-negotiable
  2. Complete treatment history with dates, responses, and reasons for discontinuation
  3. Medical necessity letter from your oncologist explaining why Pemazyre is specifically needed
  4. Baseline ophthalmologic exam (required for FGFR inhibitor monitoring)

Supporting Evidence:

  • FDA label indication matching your diagnosis
  • NCCN Guidelines supporting Pemazyre use in your situation
  • Published studies showing superiority for your specific FGFR alteration
  • Documentation of contraindications to alternatives

Exception Request Process

  1. Gather documentation (allow 1-2 weeks)
  2. Provider submits request via Aetna provider portal or fax
  3. Aetna reviews (standard: 30-45 days; expedited: 24-72 hours)
  4. Decision notification to provider and patient
  5. Appeal if denied (must start within 180 days)

Switching Logistics and Coordination

Working with CVS Specialty

Counterforce Health helps streamline the complex coordination between providers, specialty pharmacies, and payers when switching between FGFR inhibitors or appealing coverage decisions.

CVS Specialty Coordination Steps:

  1. Benefits verification for the new medication
  2. Prior authorization submission with switch rationale
  3. Supply bridge management to avoid therapy gaps
  4. Patient assistance program enrollment if needed

Provider Coordination

Your oncologist should:

  • Document clinical rationale for the switch
  • Provide detailed notes on prior therapy failure/intolerance
  • Submit new prior authorization with comparative effectiveness data
  • Coordinate timing to minimize treatment interruption

Timeline expectations:

  • Benefits verification: 1-3 business days
  • Prior authorization review: 5-10 business days
  • Appeal if denied: 30-45 days (standard) or 24-72 hours (expedited)

Re-trying for Pemazyre Later

What to Document During Alternative Therapy

Keep detailed records of:

  • Response measurements (imaging, tumor markers, clinical assessments)
  • Side effects and tolerability issues
  • Quality of life impacts
  • Disease progression with dates and evidence
  • Reasons for discontinuation if therapy fails

Timing Your Re-attempt

Best times to re-request Pemazyre:

  • After documented progression on alternative FGFR inhibitor
  • When new clinical evidence supports Pemazyre superiority
  • At plan year renewal (formulary changes)
  • Following policy updates or new FDA approvals

Strengthening Your Case

  • Reference your alternative therapy trial as satisfying step therapy
  • Highlight any unique aspects of your FGFR alteration
  • Include updated guidelines or literature supporting Pemazyre
  • Document any changes in your clinical condition

Appeals Playbook for Ohio

Aetna CVS Health Internal Appeals

Level 1 Internal Appeal:

  • Deadline: 180 days from denial
  • Timeline: 30 days standard, 72 hours expedited
  • Submission: Provider portal, fax, or mail
  • Required: Denial letter, clinical documentation, medical necessity letter

Level 2 Internal Appeal:

  • Automatic if Level 1 denied
  • Timeline: Additional 30 days
  • Enhanced review with different medical reviewers

Ohio External Review Process

If Aetna upholds their denial after internal appeals, Ohio residents can request external review through the Ohio Department of Insurance.

External Review Requirements:

  • Deadline: 180 days from final internal denial
  • Eligibility: Medical necessity denials, experimental/investigational determinations
  • Process: Independent Review Organization (IRO) conducts binding review
  • Timeline: 30 days standard, 72 hours expedited

Contact Information:

  • Ohio Department of Insurance Consumer Hotline: 1-800-686-1526
  • External Review Request Forms available at insurance.ohio.gov

When to Escalate

Consider escalating to Ohio regulators if:

  • Aetna improperly denies external review eligibility
  • Appeals exceed published timelines
  • You suspect procedural violations
  • Pattern of inappropriate denials

FAQ

How long does Aetna CVS Health prior authorization take for Pemazyre in Ohio?
Standard prior authorization decisions take 30-45 days. Expedited reviews for urgent medical needs are completed within 24-72 hours.

What if Pemazyre is completely non-formulary on my Aetna plan?
You can request a formulary exception with clinical justification. Success depends on documenting medical necessity and why formulary alternatives are inappropriate.

Can I request an expedited appeal if my cancer is progressing?
Yes. Your oncologist can request expedited review by certifying that delays would seriously jeopardize your health. Ohio law requires 72-hour decisions for expedited external reviews.

Does step therapy apply if I failed FGFR inhibitors outside Ohio?
Prior therapy documentation from any location should satisfy step therapy requirements, but you'll need complete records transferred to your current provider.

What happens if CVS Specialty can't get prior authorization approved?
CVS Specialty will work with your provider on appeals and help identify patient assistance programs. They can also coordinate with Counterforce Health for specialized coverage advocacy.

Are there financial assistance programs for Pemazyre?
Yes. Incyte offers patient assistance programs, and foundations like CancerCare provide grants. CVS Specialty can help identify and apply for appropriate programs.

How do I know if my FGFR testing is adequate for approval?
Your molecular pathology report must specifically identify FGFR2 fusions/rearrangements (for cholangiocarcinoma) or FGFR1 rearrangements (for myeloid/lymphoid neoplasms). Generic "FGFR mutation" reports may not suffice.

Can I appeal to Ohio regulators if Aetna denies my external review request?
Yes. The Ohio Department of Insurance can independently determine external review eligibility even if Aetna claims you don't qualify.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on your specific insurance plan and clinical situation. Always consult with your healthcare provider and insurance company for personalized guidance.

For additional help with Ohio health insurance appeals, contact the Ohio Department of Insurance Consumer Services at 1-800-686-1526 or visit insurance.ohio.gov.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.